Prospective trial shows luteal estradiol priming alone yields similar outcomes to combining it with GnRH antagonist in patients with diminished ovarian reserve, suggesting cost savings.
The addition of a GnRH antagonist to luteal E2 priming did not improve oocyte yield or IVF outcomes in patients with DOR. Given similar efficacy and potential cost savings, luteal E2 priming alone may be a sufficient approach. Prospective trials are needed to validate these findings.
No takes yet. Share an insight, caveat, or question.
Ghofranian et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More from Minerva Obstetrics and Gynecology